Inhibitors of canine janus kinase and uses thereof

Canine Janus Kinase inhibitors of Formula I, II, or III offer a solution to the challenges of existing treatments for atopic dermatitis by providing effective, once-daily dosing with improved tolerability and efficacy for managing chronic pruritus and inflammation.

WO2026133210A1PCT designated stage Publication Date: 2026-06-25ANIMOL DISCOVERY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2025/063088
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-12-17
Publication Date
2026-06-25

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
Patent Text Reader

Abstract

Provided herein are compounds having inhibitory activity toward the Janus Kinase 1 (JAK-1) enzyme, and which are useful as therapeutic and / or prophylactic agents. The compounds may be useful in treating inflammatory disorders in non-human mammals, for example, in treating canine atopic dermatitis. Also provided herein are methods for preparation of such compounds.
Need to check novelty before this filing date? Find Prior Art